Findings

What do systematic reviews say?

7 questions · 7 findings · 6 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 2 · 28.6%Very low 0 · 0%Low 1 · 14.3%Moderate 1 · 14.3%High 1 · 14.3%

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects: 1. Sedation · patients with schizophrenia

FLUPHENAZINE leads to lower adverse effects‐other‐sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (high certainty).

1 finding from 1 review

Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.31 [0.13, 0.77]
1 study · 65 participants
High

HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects: 1. Sedation · patients with schizophrenia

HALOPERIDOL probably leads to lower adverse effects ‐ other ‐ Sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

1 finding from 1 review

Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.3 [0.11, 0.82]
2 studies · 44 participants
Moderate

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects: 1. Sedation · patients with schizophrenia

1 finding from 1 review

Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

ZUCLOPENTHIXOL ACETATE vs placebo

Other adverse effects, general and specific · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Zuclopenthixol versus placebo for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ZUCLOPENTHIXOL DECANOATE vs placebo

Other adverse effects, general and specific · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Zuclopenthixol versus placebo for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE vs ECT

Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms

1 finding from 1 review

Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
GRADE not reported

Pyridoxal 5 phosphate (vitamin B6) vs placebo

Global: Other adverse effects than tardive dyskinesia Self‐report by participants · patients with antipsychotic‐induced tardive dyskinesia

Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Other adverse effects than tardive dyskinesia Self‐report by… compared with placebo (low certainty).

1 finding from 1 review

Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
RR 3.97 [0.2, 78.59]
2 studies · 65 participants
Low